Comparison of Immune Response in Mice Immunized with Recombinant PreS2/S-C18-27 Protein Derived from Hepatitis B Virus with Commercial Vaccine

BACKGROUND & OBJECTIVE: The vaccine available to prevent Hepatitis B virus disease is ineffective in 5% of people due to the use of HBsAg as a weak immunogenic factor. In the present study, PreS2/S fused to C18-27 peptide fragment as an effective antigen and is proposed as a promising vaccine ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Gholami Parizad, Elaheh, Imani Fooladi, Abbas Ali, Sedighian, Hamid, Behzadi, Elham, Valizadeh, Azar, Khosravi, Afra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Iranian Society of Pathology 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745760/
https://www.ncbi.nlm.nih.gov/pubmed/36532644
http://dx.doi.org/10.30699/IJP.2022.553785.2896

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745760/
https://www.ncbi.nlm.nih.gov/pubmed/36532644
http://dx.doi.org/10.30699/IJP.2022.553785.2896

Ejemplares similares